套管钻井用套管外表面磨损后剩余强度分析

在分析讨论套管钻井管柱磨损形态的基础上,结合API5C5实物试验尺寸要求,通过有限元计算分析方法,对钻井套管完钻后含有外表面磨损缺陷的套管柱的极限剩余抗挤强度和极限剩余抗拉强度进行了研究,分别获得了均匀磨损和偏磨条件下,套管钻井套管柱外表面磨损缺陷的临界长度尺寸数值,以及不同破坏失效准则条件下的剩余抗挤强度和剩余抗拉强度的计算方程,为套管钻井中套管柱的设计、计算奠定了理论基础。     

特低渗透油气藏成岩储集相的定量评价方法

针对陕北斜坡东部特低渗透储层受沉积作用和成岩作用两大因素控制的特点，利用灰色系统理论对成岩储集相进行了研究。分析了成岩作用综合效应及其相应的视压实率、视肢结率、视微孔率、成岩综合系数等定量指标和岩心分析数据，建立了成岩储集相综合评价参数、指标和分析方法。通过在安塞油田低孔隙度特低渗透长6。油藏储层的实际应用，对目的层段开展了Ⅰ，Ⅱ，Ⅲ和Ⅳ类成岩储集相的定量评价和油气富集描述，有机地集成和综合了多种信息，实现了成岩储集相对沉积学、岩石学和成岩作用等特征的综合表征，并划分出有利成岩储集相区域，为指导油田有利含油区块的筛选和开发决策提供了重要依据。     

变频调速技术在污水处理厂的应用

概述污水处理厂的一般工艺，简单介绍了风机、水泵等的节能特点，介绍了变频调速装置在污水处理厂各处理工段的应用。     

东营凹陷南斜坡储集层成岩作用及对储集性能的影响

东营凹陷南斜坡孔店组岩石类型以岩屑长石砂岩为主 ,长石砂岩和岩屑砂岩次之 ,其中岩屑长石砂岩含量超过 90 %。砂岩成岩作用包括压实作用、胶结作用、溶蚀作用、交代作用等 ,其中胶结作用使储层原生孔隙迅速变差 ,而溶蚀作用是次生空隙发育的主要因素。孔店组砂岩成岩作用进入晚成岩A期 ,期间经历了早成岩A期、B期。影响成岩作用的主要因素为构造演化背景、岩石成分、沉积环境、孔隙流体性质等。     

Noninvasive evaluation of the lower extremity arterial tree and graft surveillance

The application of duplex ultrasonography in the evaluation of lower extremity arterial occlusive disease and in graft surveillance has enhanced significantly the vascular surgeon's diagnostic armamentarium. With continued refinements in gray scale image resolution, color flow, and spectral analysis, color duplex ultrasonography eventually will replace angiographic evaluation in carefully selected patients as the primary pre-interventional testing modality.     

糖化酶制剂辐照性能研究

研究了工业糖化酶制剂经辐照处理后各项性能的变化。结果表明,经2kGy以下剂量的γ射线处理后,可提高其贮存稳定性,改善卫生品质,不影响其正常使用。     

^60Coγ射线对刚地弓形虫缓殖子感染性的影响

应用不同剂量的~(60)Coγ射线照射含NT株弓形虫包囊的鼠脑匀浆后,以0.4％胰蛋白酶液消化,使弓形虫缓殖子从包囊中释放出来,并用生理盐水作连续10倍稀释,使成为含不同数量缓殖子的悬液,将此悬液接种小鼠,用生物检测方法确定其感染性。另设未经照射处理的缓殖子悬液感染小鼠的对照组。结果表明,γ射线0.55kGy剂量为控制鼠脑中NT株弓形虫感染性的最小有效剂量。γ射线0.1kGy剂量对弓形虫缓殖子感染性无明显影响,而0.45kGy照射后,其感染性较前者下降了10~4倍。     

过共晶Al－Si合金共生区激光表面处理

用２ｋＷ连续ＣＯ２激光对过共晶Ａｌ－１８Ｓｉ合金以不同能量密度和扫描速度进行快速熔凝处理。用扫描电镜、电子微区分析仪分析了微观结构。从计算机对Ａｌ－Ｓｉ合金ｆ－ｎｆ系统的非平衡理论计算所得的共生区及实验结果的分析可见，当能量密度和扫描速度决定的凝固条件处于共生区中部时，过共晶Ａｌ－Ｓｉ合金激光表面处理可以得到共晶间距低于２００ｎｍ的完全共晶结构。     

Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support

4-Hydroperoxycyclophosphamide (4-HC), a commonly used marrow-purging agent, is active against many tumors, but is also toxic to normal marrow progenitors. Amifostine (WR-2721) is a sulfhydryl compound with chemoprotectant activity. Preclinical studies using suspensions of bone marrow and breast cancer cells demonstrated that ex vivo treatment with amifostine followed by 4-HC resulted in protection of marrow progenitors, with no compromise in the antitumor effect of 4-HC. This fact stimulated the development of a clinical trial. Bone marrow was harvested from 15 poor-prognosis breast cancer patients and randomly assigned to ex vivo treatment with amifostine followed by 4-HC (amifostine + 4-HC), or treatment with 4-HC alone. High-dose chemotherapy was then administered followed by infusion of the purged autologous bone marrow support (ABMS). Leukocyte engraftment, defined as a white blood cell count > or = 1 x 10(9)/L, was achieved in an average of 26 days for patients whose marrow was purged with amifostine + 4-HC versus 36 days for patients whose marrow was purged with 4-HC alone (P = .032). The average number of platelet transfusions (12 v 29; P = .017) and days of antibiotic therapy (28 v 40; P = .012) were significantly less for patients whose marrow was exposed to amifostine + 4-HC, compared with 4-HC alone. Unpurged backup marrow fractions were infused into three patients whose marrow was purged with 4-HC alone, because of inadequate marrow recovery. None of the patients who received amifostine + 4-HC-purged marrow required a backup marrow fraction. Complete remissions were achieved in 83% of patients with measurable disease, with no difference between the two cohorts. Forty-three percent of patients remained alive and progression-free at a mean of 13 months posttransplant. There was no significant difference in the rate or pattern of relapse for patients whose marrow was purged with amifostine + 4-HC compared with those whose marrow was purged with 4-HC alone. Ex vivo treatment of marrow with amifostine significantly shortens the time to marrow recovery, thereby reducing the risk of myelosuppressive complications in breast cancer patients receiving high-dose chemotherapy and 4-HC-purged ABMS. Since supportive care requirements are also significantly decreased, amifostine may reduce the cost of such therapy.     

FED制作工艺研究

本文介绍了我们开发的ＦＥＤ工艺，包括；硅锥场致发射阵列的制作，栅极制作，阳极支柱的制作和平板透明真空封装，对工艺中的难点及对策作了详细描述。利用上述工艺，已经制成了平板数码管，其栅阴特性理想，阳阴之间也能测得明显的场致发射特性产伴有荧光激发。